EspB and HtpG interact with the type III-A CRISPR/Cas system of Mycobacterium tuberculosis

Mingmin Shi1,2, Hongtai Zhang3, Joy Fleming2

  • 1Foshan Fourth People's Hospital, Foshan, China.

PubMed

Insights

Two novel proteins, EspB and HtpG, are involved in Mycobacterium tuberculosis's CRISPR/Cas system. EspB binds crRNA, while HtpG inhibits Csm protein accumulation, impacting bacterial defense mechanisms and offering potential for TB diagnostics and vaccines.

Area of Science:

  • Molecular Biology
  • Microbiology
  • Immunology

Background:

  • Mycobacterium tuberculosis (MTB) possesses a type III-A CRISPR/Cas system for defense against foreign nucleic acids.
  • The specific roles and components of the MTB CRISPR/Cas system remain largely uncharacterized.

Purpose of the Study:

  • To identify and characterize novel proteins involved in the MTB type III-A CRISPR/Cas system.
  • To elucidate the distinct functions of identified proteins, EspB and HtpG, within this system.

Main Methods:

  • Proteins EspB and HtpG were identified using Liquid Chromatography-Mass Spectrometry/Mass Spectrometry (LC-MS/MS).
  • Functional roles were assessed via plasmid interference assays and co-immunoprecipitation analyses.
  • Interactions with the CRISPR RNA ribonucleoprotein (crRNP) complex and Csm proteins were investigated.

Main Results:

  • EspB was identified as a novel crRNA-binding protein that directly interacts with the MTB crRNP complex.
  • HtpG was found to inhibit the accumulation of MTB Csm proteins, thereby interfering with the CRISPR/Cas defense mechanism.
  • Both EspB and HtpG, previously unassociated with CRISPR/Cas, play distinct roles in mycobacterial defense.

Conclusions:

  • EspB is a novel crRNA-binding protein crucial for the MTB CRISPR/Cas system's function.
  • HtpG modulates Csm protein levels and impacts the overall efficacy of the crRNP complex against foreign DNA.
  • These findings offer potential for developing new clinical diagnostic tools and vaccine candidates for tuberculosis (TB).